ドライ型加齢黄斑変性（AMD）の世界市場レポート 2025年

ドライ型加齢黄斑変性（AMD）市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.8％で68億6,000万米ドルに成長します。予測期間中の成長は、新たな治療法の出現、ヘルスケア支出の増加、レーザー光凝固療法の利用拡大、遺伝子研究の進歩、個別化医療の重視の高まりによってもたらされます。主な動向としては、診断技術の革新、遠隔眼科の採用増加、技術的に高度な治療法の開発、規制当局の承認、新製品の発売などが挙げられます。

老年人口の増加は、ドライ型加齢黄斑変性（AMD）市場の成長を牽引すると予想されます。老年人口とは高齢者を指し、一般的には65歳以上の個人と定義されます。この人口層の増加は、医療技術の進歩、慢性疾患の管理の向上、平均寿命の延伸、老人医療の改善によってもたらされています。ドライ型AMDは、疾患の進行を遅らせ、視力を維持し、高齢者の生活の質を高めることを目的とした、的を絞った治療や管理方法を提供することで、高齢化社会を支える重要な役割を担っています。例えば、2024年6月、米国を拠点とする団体National Council on Agingの報告書によると、2022年には65歳以上の成人は約5,780万人で、米国総人口の17.3%を占め、2021年の16.9%から増加しています。その結果、高齢者人口の増加がドライAMD市場の拡大に拍車をかけると予想されます。

ドライ型AMD市場の主要企業は、網膜細胞を標的として活性化し、疾患の進行を遅らせる可能性のある光送達システムなどの先進技術や治療法の開発に注力しています。光伝送システムは、特に治療用途に光を伝送するように設計されています。例えば、2024年1月、米国の医療機器会社LumiThera Inc.は、Valeda Light Delivery SystemによるドライAMDの光バイオモジュレーション（PBM）療法を発表しました。これは、治療の選択肢が限られているドライ型AMD患者の視力低下に対処することを目的とした初のFDA認可治療です。ルミセラはまた、Valedaシステムの転帰に関する長期的な患者データを収集するEUROLIGHTレジストリ研究を開始しました。Valedaシステムは、3つの特定波長（590nm、660nm、850nm）を持つ多波長光照射方式を採用しています。この非侵襲的治療は、まぶたを開いた状態または閉じた状態から行うことができ、通常3～4週間にわたり9回のセッションが必要です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ドライ型加齢黄斑変性（AMD） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のドライ型加齢黄斑変性（AMD）市場：成長率分析
• 世界のドライ型加齢黄斑変性（AMD）市場の実績：規模と成長, 2019-2024
• 世界のドライ型加齢黄斑変性（AMD）市場の予測：規模と成長, 2024-2029, 2034F
• 世界ドライ型加齢黄斑変性（AMD）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のドライ型加齢黄斑変性（AMD）市場ステージ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 早期加齢黄斑変性
• 中期加齢黄斑変性
• 加齢黄斑変性症
• 世界のドライ型加齢黄斑変性（AMD）市場：年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 75歳以上
• 60歳以上
• 40歳以上
• 世界のドライ型加齢黄斑変性（AMD）市場投与経路、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• 世界のドライ型加齢黄斑変性（AMD）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 診断センター
• 学術研究機関
• 世界のドライ型加齢黄斑変性（AMD）市場早期加齢黄斑変性症の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドルーゼン蓄積
• 網膜色素上皮の変化
• 世界のドライ型加齢黄斑変性（AMD）市場中期加齢黄斑変性症の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• より大きなドルーゼン沈着物
• 色素異常の増加
• 世界のドライ型加齢黄斑変性（AMD）市場、加齢黄斑変性症の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 地図状萎縮
• 中心視力喪失

第7章 地域別・国別分析

• 世界のドライ型加齢黄斑変性（AMD）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のドライ型加齢黄斑変性（AMD）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ドライ型加齢黄斑変性（AMD）市場：競合情勢
• ドライ型加齢黄斑変性（AMD）市場：企業プロファイル
  • F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Astellas Pharma Inc.
• Bausch Health Companies Inc.
• Lupin Ltd.
• Santen Pharmaceuticals Inc.
• Biocon Ltd.
• Alimera Sciences Inc.
• Apellis Pharmaceuticals Inc.
• Belite Bio Inc.
• Axol Bioscience Ltd.
• Alkeus Pharmaceuticals Inc.
• Kubota Holdings Co.
• Ribomic Inc.
• Eyestem Research Pvt. Ltd.
• LumiThera Inc.
• Adverum Biotechnologies Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ドライ型加齢黄斑変性（AMD）市場2029：新たな機会を提供する国
• ドライ型加齢黄斑変性（AMD）市場2029：新たな機会を提供するセグメント
• ドライ型加齢黄斑変性（AMD）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Dry age-related macular degeneration (AMD) is a progressive eye condition that involves the gradual deterioration of the macula, the central part of the retina, leading to blurred central vision. Treatment options, including vitamins, nutritional supplements, and emerging pharmaceutical therapies, aim to manage and slow the disease's progression.

The main stages of dry AMD are early age-related macular degeneration, intermediate age-related macular degeneration, and late age-related macular degeneration. Early AMD is the initial stage of this common eye condition, which primarily affects older adults and causes changes in the retina, specifically the macula, responsible for central vision. It affects various age groups, including those above 40, 60, and 75 years. Treatment is administered through different routes, such as oral and injectable forms, and is utilized by various end users, including hospitals, clinics, diagnostic centers, and academic and research institutes.

The dry age related macular degeneration (AMD) market research report is one of a series of new reports from The Business Research Company that provides dry age related macular degeneration (AMD) market statistics, including dry age related macular degeneration (AMD) industry global market size, regional shares, competitors with a dry age related macular degeneration (AMD) market share, detailed dry age related macular degeneration (AMD) market segments, market trends and opportunities, and any further data you may need to thrive in the dry age related macular degeneration (AMD) industry. This dry age related macular degeneration (AMD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dry age related macular degeneration (AMD) market size has grown strongly in recent years. It will grow from $4.49 billion in 2024 to $4.90 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth during the historic period was driven by a rising aging population, an increased prevalence of chronic diseases, greater awareness of eye health, a growing number of clinical trials focused on dry AMD, and increasing demand for minimally invasive treatments.

The dry age related macular degeneration (AMD) market size is expected to see strong growth in the next few years. It will grow to $6.86 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The projected growth during the forecast period is driven by emerging novel therapies, increasing healthcare expenditure, greater utilization of laser photocoagulation therapy, advancements in genetic research, and a growing emphasis on personalized medicine. Key trends include innovations in diagnostic technologies, the rising adoption of teleophthalmology, the development of technologically advanced treatments, regulatory approvals, and new product launches.

The increasing geriatric population is expected to drive the growth of the dry age-related macular degeneration (AMD) market. The geriatric population refers to older adults, typically defined as individuals aged 65 and older. The rise in this demographic is driven by advancements in medical technology, better management of chronic diseases, increased life expectancy, and improved geriatric care. Dry AMD plays a crucial role in supporting the aging population by providing targeted treatments and management options aimed at slowing disease progression, preserving vision, and enhancing the quality of life for older individuals affected by the condition. For example, in June 2024, a report by the National Council on Aging, a US-based organization, stated that in 2022, there were approximately 57.8 million adults aged 65 and older, making up 17.3% of the total U.S. population, an increase from 16.9% in 2021. As a result, the growing geriatric population is expected to fuel the expansion of the dry AMD market.

Leading companies in the dry AMD market are focusing on developing advanced technologies and treatments, such as light delivery systems, to target and activate retinal cells, potentially slowing disease progression. Light delivery systems are designed to transmit light for therapeutic applications, particularly in medical treatments. For instance, in January 2024, LumiThera Inc., a US-based medical device company, introduced photobiomodulation (PBM) therapy for dry AMD through the Valeda Light Delivery System. This is the first FDA-authorized therapy aimed at addressing vision loss in patients with dry AMD, a condition with limited treatment options. LumiThera also launched the EUROLIGHT registry study to collect long-term patient data on Valeda system outcomes. The Valeda system uses a multi-wavelength light delivery method with three specific wavelengths (590 nm, 660 nm, and 850 nm). This non-invasive treatment can be administered through an open or closed eyelid and typically requires nine sessions over three to four weeks.

In May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired IVERIC Bio Inc. for $5.9 billion. This acquisition strengthens Astellas Pharma's presence in the ophthalmology market and accelerates the development of innovative treatments for retinal diseases, improving patient outcomes worldwide. IVERIC Bio Inc., a US-based biotech company, specializes in the development of age-related macular degeneration drugs and related treatments, further enhancing Astellas Pharma's research and development capabilities in the field.

Major players in the dry age related macular degeneration (AMD) market are F Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Amgen Inc., Biogen Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Lupin Ltd., Santen Pharmaceuticals Inc., Biocon Ltd., Alimera Sciences Inc., Apellis Pharmaceuticals Inc., Belite Bio Inc., Axol Bioscience Ltd., Alkeus Pharmaceuticals Inc., Kubota Holdings Co., Ribomic Inc., Eyestem Research Pvt. Ltd., LumiThera Inc., Adverum Biotechnologies Inc.

North America was the largest region in the dry age-related macular degeneration (AMD) market in 2024. The regions covered in dry age-related macular degeneration (AMD) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dry age related macular degeneration (AMD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dry age related macular degeneration (AMD) market consists of sales of syfovre, zimura, visudyne, and alk-001. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dry Age Related Macular Degeneration (AMD) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dry age related macular degeneration (amd) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dry age related macular degeneration (amd) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dry age related macular degeneration (amd) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Stages: Early Age-Related Macular Degeneration; Intermediate Age-Related Macular Degeneration; Late Age-Related Macular Degeneration
• 2) By Age Group: Above 75 Years; Above 60 Years; Above 40 Years
• 3) By Route Of Administration: Oral; Injectables
• 4) By End Users: Hospitals And Clinics; Diagnostic Centers; Academic And Research Institutes
• Subsegments:
• 1) By Early Age-Related Macular Degeneration: Drusen Accumulation; Retinal Pigment Epithelium Changes
• 2) By Intermediate Age-Related Macular Degeneration: Larger Drusen Deposits; Increased Pigmentary Abnormalities
• 3) By Late Age-Related Macular Degeneration: Geographic Atrophy; Central Vision Loss
• Companies Mentioned: F Hoffmann-La Roche Ltd.; Novartis AG; Bayer AG; Amgen Inc.; Biogen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Dry Age Related Macular Degeneration (AMD) Market Characteristics

3. Dry Age Related Macular Degeneration (AMD) Market Trends And Strategies

4. Dry Age Related Macular Degeneration (AMD) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Dry Age Related Macular Degeneration (AMD) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Dry Age Related Macular Degeneration (AMD) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Dry Age Related Macular Degeneration (AMD) Market Growth Rate Analysis
• 5.4. Global Dry Age Related Macular Degeneration (AMD) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Dry Age Related Macular Degeneration (AMD) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Dry Age Related Macular Degeneration (AMD) Total Addressable Market (TAM)

6. Dry Age Related Macular Degeneration (AMD) Market Segmentation

• 6.1. Global Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early Age-Related Macular Degeneration
• Intermediate Age-Related Macular Degeneration
• Late Age-Related Macular Degeneration
• 6.2. Global Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Above 75 Years
• Above 60 Years
• Above 40 Years
• 6.3. Global Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectables
• 6.4. Global Dry Age Related Macular Degeneration (AMD) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Diagnostic Centers
• Academic And Research Institutes
• 6.5. Global Dry Age Related Macular Degeneration (AMD) Market, Sub-Segmentation Of Early Age-Related Macular Degeneration, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drusen Accumulation
• Retinal Pigment Epithelium Changes
• 6.6. Global Dry Age Related Macular Degeneration (AMD) Market, Sub-Segmentation Of Intermediate Age-Related Macular Degeneration, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Larger Drusen Deposits
• Increased Pigmentary Abnormalities
• 6.7. Global Dry Age Related Macular Degeneration (AMD) Market, Sub-Segmentation Of Late Age-Related Macular Degeneration, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Geographic Atrophy
• Central Vision Loss

7. Dry Age Related Macular Degeneration (AMD) Market Regional And Country Analysis

• 7.1. Global Dry Age Related Macular Degeneration (AMD) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Dry Age Related Macular Degeneration (AMD) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Dry Age Related Macular Degeneration (AMD) Market

• 8.1. Asia-Pacific Dry Age Related Macular Degeneration (AMD) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Dry Age Related Macular Degeneration (AMD) Market

• 9.1. China Dry Age Related Macular Degeneration (AMD) Market Overview
• 9.2. China Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Dry Age Related Macular Degeneration (AMD) Market

• 10.1. India Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Dry Age Related Macular Degeneration (AMD) Market

• 11.1. Japan Dry Age Related Macular Degeneration (AMD) Market Overview
• 11.2. Japan Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Dry Age Related Macular Degeneration (AMD) Market

• 12.1. Australia Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Dry Age Related Macular Degeneration (AMD) Market

• 13.1. Indonesia Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Dry Age Related Macular Degeneration (AMD) Market

• 14.1. South Korea Dry Age Related Macular Degeneration (AMD) Market Overview
• 14.2. South Korea Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Dry Age Related Macular Degeneration (AMD) Market

• 15.1. Western Europe Dry Age Related Macular Degeneration (AMD) Market Overview
• 15.2. Western Europe Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Dry Age Related Macular Degeneration (AMD) Market

• 16.1. UK Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Dry Age Related Macular Degeneration (AMD) Market

• 17.1. Germany Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Dry Age Related Macular Degeneration (AMD) Market

• 18.1. France Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Dry Age Related Macular Degeneration (AMD) Market

• 19.1. Italy Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Dry Age Related Macular Degeneration (AMD) Market

• 20.1. Spain Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Dry Age Related Macular Degeneration (AMD) Market

• 21.1. Eastern Europe Dry Age Related Macular Degeneration (AMD) Market Overview
• 21.2. Eastern Europe Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Dry Age Related Macular Degeneration (AMD) Market

• 22.1. Russia Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Dry Age Related Macular Degeneration (AMD) Market

• 23.1. North America Dry Age Related Macular Degeneration (AMD) Market Overview
• 23.2. North America Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Dry Age Related Macular Degeneration (AMD) Market

• 24.1. USA Dry Age Related Macular Degeneration (AMD) Market Overview
• 24.2. USA Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Dry Age Related Macular Degeneration (AMD) Market

• 25.1. Canada Dry Age Related Macular Degeneration (AMD) Market Overview
• 25.2. Canada Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Dry Age Related Macular Degeneration (AMD) Market

• 26.1. South America Dry Age Related Macular Degeneration (AMD) Market Overview
• 26.2. South America Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Dry Age Related Macular Degeneration (AMD) Market

• 27.1. Brazil Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Dry Age Related Macular Degeneration (AMD) Market

• 28.1. Middle East Dry Age Related Macular Degeneration (AMD) Market Overview
• 28.2. Middle East Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Dry Age Related Macular Degeneration (AMD) Market

• 29.1. Africa Dry Age Related Macular Degeneration (AMD) Market Overview
• 29.2. Africa Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Dry Age Related Macular Degeneration (AMD) Market Competitive Landscape And Company Profiles

• 30.1. Dry Age Related Macular Degeneration (AMD) Market Competitive Landscape
• 30.2. Dry Age Related Macular Degeneration (AMD) Market Company Profiles
  • 30.2.1. F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Dry Age Related Macular Degeneration (AMD) Market Other Major And Innovative Companies

• 31.1. Astellas Pharma Inc.
• 31.2. Bausch Health Companies Inc.
• 31.3. Lupin Ltd.
• 31.4. Santen Pharmaceuticals Inc.
• 31.5. Biocon Ltd.
• 31.6. Alimera Sciences Inc.
• 31.7. Apellis Pharmaceuticals Inc.
• 31.8. Belite Bio Inc.
• 31.9. Axol Bioscience Ltd.
• 31.10. Alkeus Pharmaceuticals Inc.
• 31.11. Kubota Holdings Co.
• 31.12. Ribomic Inc.
• 31.13. Eyestem Research Pvt. Ltd.
• 31.14. LumiThera Inc.
• 31.15. Adverum Biotechnologies Inc.

32. Global Dry Age Related Macular Degeneration (AMD) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dry Age Related Macular Degeneration (AMD) Market

34. Recent Developments In The Dry Age Related Macular Degeneration (AMD) Market

35. Dry Age Related Macular Degeneration (AMD) Market High Potential Countries, Segments and Strategies

• 35.1 Dry Age Related Macular Degeneration (AMD) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Dry Age Related Macular Degeneration (AMD) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Dry Age Related Macular Degeneration (AMD) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer